News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dompé: The First International Clinical Ophthalmological Trial Concerning Treatment of Neurotrophic Keratitis (NK), an Ocular Pathology With No Cure, Takes Place in Italy


9/7/2012 10:25:56 AM

MILANO--(BUSINESS WIRE)--Dompé, one of the leading biopharmaceutical companies in Italy, announced today that it has initiated a Phase I clinical trial on the use of recombinant human Nerve Growth Factor (rhNGF), the discovery of which earned Professor Rita Levi Montalcini a Nobel Prize, for treating neurotrophic keratitis, a rare ocular pathology which still has no cure, and affects one person in 10,000 worldwide.

Read at BioSpace.com

comments powered by Disqus
Dompe
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES